ODI Pharma

ODI Pharma, is a producer of pharmaceutical cannabis finished products with a focus on distribution to medicinal markets in Europe...

[ODI Pharma @OdiPharma]

The Company has achieved record sales levels, and year-to-date sales already exceed any previous full fiscal year in ODI Pharma’s history. #medicalcannabis #cannabis #medicinalcannabis #marichuana #CannabisIndustry
#CannabisInvestors #odipharma

https://t.co/328FdSxmGR

[ODI Pharma @OdiPharma]

The Company has achieved record sales levels, and year-to-date sales already exceed any previous full fiscal year in ODI Pharma’s history. #medicalcannabis #cannabis #medicinalcannabis #marichuana #CannabisIndustry
#CannabisInvestors #odipharma

https://t.co/328FdSxmGR

[ODI Pharma @OdiPharma]

Significantly strong revenue development for the period October–December 2025 (Q2) by 84%.

https://t.co/qp35P9eik8

[ODI Pharma @OdiPharma]

ODI Pharma achieved market share targets in 2024 and increases its targets for 2025. Positioned for growth as Poland's medical cannabis market expands.
https://t.co/tSTY9708CD
#cannabis

[ODI Pharma @OdiPharma]

Publication of year-end report for the fiscal year 2023/2024
https://t.co/faG7ZlwnNJ
#cannabis #medicine #medical

[ODI Pharma @OdiPharma]

The third quarter of this fiscal year has been marked by significant achievements and impressive revenue growth, reflecting our ongoing efforts to expand and solidify our presence in the medicinal cannabis sector.
https://t.co/A4x69jB5aI
#medicinalcannabis
#medicalcannabis

[Cision News @CisionNews]

Preliminary results for ODI Pharma indicate significant revenue increase in Q3 2023/2024 https://t.co/m5AC9JkdOf

[ODI Pharma @OdiPharma]

Preliminary results for ODI Pharma indicate significant revenue increase in Q3 2023/2024 -> SEK 13.5 million. This growth mainly comes from an increase in orders following our strategic partnership in Eastern Europe.

https://t.co/hX8S4wf1iZ

[ODI Pharma @OdiPharma]

ODI Pharma AB enters into exclusive collaboration with Synoptis Pharma Sp. z o.o.
https://t.co/QyAf0PYNdb

[Finwire Smallcap @FinwireSmallcap]

Odi Pharma ett steg närmare lansering i Polen efter godkänd MAH-ansökan, ökar förlusten i Q2 https://t.co/hRwYyzQWk7 #healthcare #interim #lifescience #pharmaceuticals #stocks

[Cision News @CisionNews]

ODI Pharma receives approval from the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in Poland to distribute and sell its products on the Polish market https://t.co/ovo8CtC8yN

[Nyemissioner.se @Nyemissioner]

ODI Pharma, som fokuserar på att börja sälja medicinsk cannabis i Polen, har nu fått godkännande att göra det. https://t.co/JAGuOcQIc3

[Finwire Smallcap @FinwireSmallcap]

Odi Pharma får grönt ljus i Polen https://t.co/P5sJqVnjXV #healthcare #lifescience #pharmaceuticals

[Spliffa.se @spliffa_se]

Företaget Odi Pharma har nu fått gr��nt ljus att distribuera och sälja sina medicinska cannabisprodukter på den polska marknaden. #medicin #cannabis #polen #vårdpol
https://t.co/5Vkh1f0eZe

[ODI Pharma @OdiPharma]

Pround to announce - ODI Pharma receives approval from the Office for Registration of Medicinal Products in Poland https://t.co/U4Bh6kyvHK

[ODI Pharma @OdiPharma]

Please tune in a podcast Q&A today at 6 pm with the CEO from ODI Pharma AB. #medicalcannabis

https://t.co/se3nht05N2

[ODI Pharma @OdiPharma]

Please tune in a podcast Q&A at 19 Oct 2021, 6 pm with the CEO from ODI Pharma AB.

https://t.co/Xi8wBHjGqo

[ODI Pharma @OdiPharma]

https://t.co/ZJfWZqURT5

[Irwin D. Simon @IrwinDSimon]

We are pleased to announce our supply agreement with ODI Pharma, which expands our presence of Aphria, our medical brand, into Poland. To learn more https://t.co/SGCEI3dmwj #WeHaveAGoodThingGrowing $APHA